PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
NCT ID: NCT06960954
Last Updated: 2025-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
116 participants
OBSERVATIONAL
2025-01-15
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.
Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
NCT04055389
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
NCT01999179
Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients
NCT02802605
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
NCT02247414
Excessive Warfarin Anticoagulation - Causes and Consequences
NCT02761941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCC patients with PVTT.
58 HCC patients with PVTT.
Prothrombin induced by vitamin K absence II (PIVKA-II)
Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
HCC Patients without PVTT.
58 HCC Patients without PVTT.
Prothrombin induced by vitamin K absence II (PIVKA-II)
Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prothrombin induced by vitamin K absence II (PIVKA-II)
Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with confirmed HCC with or without PVTT (Diagnosed by two imaging modalities or one imaging modality with elevated serum alpha fetoprotein or liver biopsy).
Exclusion Criteria
* Patients on vitamin K, vitamin K antagonists or antibiotics.
* Patients with cholestasis.
* Patients with renal insufficiency.
* Patients with other malignancies.
* Unwilling to participate in our study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Mamdouh Elkafoury
Lecturer of Tropical medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rania M Elkafoury, MD
Role: STUDY_DIRECTOR
Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University Hospitals
Tanta, Gharbyea, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264PR1127/3/25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.